Compare TBLA & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBLA | ENOV |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | 2000 | N/A |
| Industry | Computer Software: Programming Data Processing | Fluid Controls |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2008 |
| Metric | TBLA | ENOV |
|---|---|---|
| Price | $5.57 | $25.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $5.00 | ★ $47.38 |
| AVG Volume (30 Days) | ★ 3.9M | 1.3M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.63 | $6.36 |
| Revenue Next Year | $5.25 | $5.31 |
| P/E Ratio | $42.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.84 | $19.14 |
| 52 Week High | $5.71 | $34.28 |
| Indicator | TBLA | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 66.56 | 59.70 |
| Support Level | $3.86 | $21.02 |
| Resistance Level | N/A | $27.11 |
| Average True Range (ATR) | 0.24 | 1.51 |
| MACD | 0.07 | 0.54 |
| Stochastic Oscillator | 89.02 | 90.35 |
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.